196 related articles for article (PubMed ID: 29550830)
1. Consolidation Chemotherapy Prevents Relapse by Indirectly Regulating Bone Marrow Adipogenesis in Patients with Acute Myeloid Leukemia.
Liu H; Zhai Y; Zhao W; Wan Y; Lu W; Yang S; Yu Y; Wei Y; Li Z; Shi J
Cell Physiol Biochem; 2018; 45(6):2389-2400. PubMed ID: 29550830
[TBL] [Abstract][Full Text] [Related]
2. Growth differentiation factor 15 contributes to marrow adipocyte remodeling in response to the growth of leukemic cells.
Lu W; Wan Y; Li Z; Zhu B; Yin C; Liu H; Yang S; Zhai Y; Yu Y; Wei Y; Shi J
J Exp Clin Cancer Res; 2018 Mar; 37(1):66. PubMed ID: 29566722
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells.
Zhai Y; Zhang J; Wang H; Lu W; Liu S; Yu Y; Weng W; Ding Z; Zhu Q; Shi J
J Exp Clin Cancer Res; 2016 Sep; 35(1):147. PubMed ID: 27643489
[TBL] [Abstract][Full Text] [Related]
4. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
[TBL] [Abstract][Full Text] [Related]
5. Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.
Ye L; Gao L; Cheng Q; Guo F; He L; Yuan T; Zhu M; Ma Y; Pan M; Chu X; Ding M; Yu G
Medicine (Baltimore); 2021 Jan; 100(3):e24273. PubMed ID: 33546048
[TBL] [Abstract][Full Text] [Related]
6. Abnormal adipogenic signaling in the bone marrow mesenchymal stem cells contributes to supportive microenvironment for leukemia development.
Sabbah R; Saadi S; Shahar-Gabay T; Gerassy S; Yehudai-Resheff S; Zuckerman T
Cell Commun Signal; 2023 Oct; 21(1):277. PubMed ID: 37817179
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine.
Tabe Y; Saitoh K; Yang H; Sekihara K; Yamatani K; Ruvolo V; Taka H; Kaga N; Kikkawa M; Arai H; Miida T; Andreeff M; Spagnuolo PA; Konopleva M
Sci Rep; 2018 Nov; 8(1):16837. PubMed ID: 30442990
[TBL] [Abstract][Full Text] [Related]
9. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
10. Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
Ullah K; Ahmed P; Raza S; Satti TM; Chaudhry QU; Akhtar F; Kamal MK; Akhtar FM; Khan B
J Pak Med Assoc; 2007 Sep; 57(9):434-9. PubMed ID: 18072636
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche.
Boyd AL; Reid JC; Salci KR; Aslostovar L; Benoit YD; Shapovalova Z; Nakanishi M; Porras DP; Almakadi M; Campbell CJV; Jackson MF; Ross CA; Foley R; Leber B; Allan DS; Sabloff M; Xenocostas A; Collins TJ; Bhatia M
Nat Cell Biol; 2017 Nov; 19(11):1336-1347. PubMed ID: 29035359
[TBL] [Abstract][Full Text] [Related]
12. Leukemia cells remodel marrow adipocytes via TRPV4-dependent lipolysis.
Yang S; Lu W; Zhao C; Zhai Y; Wei Y; Liu J; Yu Y; Li Z; Shi J
Haematologica; 2020 Nov; 105(11):2572-2583. PubMed ID: 33131246
[TBL] [Abstract][Full Text] [Related]
13. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
[TBL] [Abstract][Full Text] [Related]
14. The bone marrow microenvironment - Home of the leukemic blasts.
Shafat MS; Gnaneswaran B; Bowles KM; Rushworth SA
Blood Rev; 2017 Sep; 31(5):277-286. PubMed ID: 28318761
[TBL] [Abstract][Full Text] [Related]
15. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
16. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
17. Optimal dose and schedule of consolidation in AML: is there a standard?
Schiffer CA
Best Pract Res Clin Haematol; 2014; 27(3-4):259-64. PubMed ID: 25455275
[TBL] [Abstract][Full Text] [Related]
18. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
19. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
20. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
